GLP-1 S the science.

Semaglutide is a synthetic peptide based on human GLP-1, engineered for a long duration of action through amino-acid substitutions and a fatty-acid chain that promotes albumin binding. These modifications allow once-weekly dosing in the studied formulations and resist rapid breakdown by the enzyme DPP-4.

As a prescription medicine, semaglutide is FDA-approved and in widespread clinical use for type 2 diabetes and for chronic weight management. The compound discussed on this page is supplied strictly as a research material and is not the approved pharmaceutical product.

Semaglutide research is built around the incretin system:

• GLP-1 receptor — activation enhances glucose-dependent insulin secretion from the pancreas.
• Satiety signaling — central GLP-1 receptor activity is studied for its effects on appetite and food intake.
• Gastric emptying — slowed gastric emptying is examined as part of the metabolic and tolerability profile.

Semaglutide has one of the largest human clinical evidence bases of any peptide in this catalog:

• Obesity trials (STEP program). A randomized, placebo-controlled trial published in the New England Journal of Medicine reported substantial body-weight reduction over 68 weeks in adults with overweight or obesity.
• Diabetes & cardiovascular research. Semaglutide has been evaluated across extensive randomized trials in type 2 diabetes and cardiovascular-outcome settings.

These findings come from trials of the medicine under medical supervision. They are reported here as research context and do not represent claims about the research material supplied on this page.

Semaglutide is supported by extensive human clinical-trial data and is approved as a prescription medicine. That approval applies to the pharmaceutical product under medical supervision — not to research material. The compound supplied here is for research use only, not for human or veterinary use, and no dosing or therapeutic claim is made about it.